203 related articles for article (PubMed ID: 29081307)
41. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
44. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
Ball S; Marangell LB; Lipsius S; Russell JM
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
[TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
[TBL] [Abstract][Full Text] [Related]
46. Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
Allgulander C; Florea I; Huusom AK
Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482
[TBL] [Abstract][Full Text] [Related]
47. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
48. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
49. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
Montgomery SA; Locklear JC; Svedsäter H; Eriksson H
Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
[TBL] [Abstract][Full Text] [Related]
51. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
52. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
53. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Allgulander C; Jørgensen T; Wade A; François C; Despiegel N; Auquier P; Toumi M
Curr Med Res Opin; 2007 Oct; 23(10):2543-9. PubMed ID: 17825130
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
Fresquet A; Sust M; Lloret A; Murphy MF; Carter FJ; Campbell GM; Marion-Landais G
Ann Pharmacother; 2000 Feb; 34(2):147-53. PubMed ID: 10676820
[TBL] [Abstract][Full Text] [Related]
55. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
56. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
57. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
[TBL] [Abstract][Full Text] [Related]
58. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
Woelk H; Schläfke S
Phytomedicine; 2010 Feb; 17(2):94-9. PubMed ID: 19962288
[TBL] [Abstract][Full Text] [Related]
59. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.
Florea I; Loft H; Danchenko N; Rive B; Brignone M; Merikle E; Jacobsen PL; Sheehan DV
Brain Behav; 2017 Mar; 7(3):e00622. PubMed ID: 28293465
[TBL] [Abstract][Full Text] [Related]
60. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Brawman-Mintzer O; Knapp RG; Nietert PJ
J Clin Psychiatry; 2005 Oct; 66(10):1321-5. PubMed ID: 16259547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
